PMID- 33132051
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 30
IP  - 5
DP  - 2021 May
TI  - Prevalence of Familial Hypercholesterolaemia in Acute Coronary Syndrome Patients 
      in a Large Regional Coronary Care Unit.
PG  - 730-733
LID - S1443-9506(20)31415-3 [pii]
LID - 10.1016/j.hlc.2020.09.929 [doi]
AB  - BACKGROUND: Familial hypercholesterolaemia (FH) is an under recognised cause of 
      coronary artery disease, despite the proven reductions in risk with early 
      detection and treatment. METHODS: Data from 180 consecutive patients presenting 
      to a large regional hospital with acute coronary syndrome were collected. 
      Potential FH was assessed using the Dutch Lipid Clinic Network Criteria (DLCNC), 
      and if patients were on statins, pre-treatment cholesterol was estimated 
      according to a validated algorithm. RESULTS: Ninety per cent (90%) of patients 
      presented with non-ST elevation myocardial infarction (NSTEMI) or ST elevation 
      myocardial infarction (STEMI). A total of 11 patients (6%) were classified as 
      having phenotypic FH. The phenotypic FH cohort was younger (mean age 53.1 vs 
      62.0, p=0.011); and more likely to have documented ischaemic heart disease (63.6% 
      vs 20.7%, p=0.001). PHENOTYPIC FH PATIENTS: Familial hypercholesterolaemia 
      patients had a higher rate of ezetimibe use (18.2% vs 2.4%, p=0.005), but fibrate 
      use was not significantly different. Phenotypic FH patients also had higher 
      levels of total cholesterol, corrected LDL and triglycerides, but no 
      statistically significant difference in HDL levels compared with non-FH 
      counterparts. CONCLUSIONS: The prevalence of FH is relatively high among patients 
      presenting with acute coronary syndromes. This has now been established in a 
      regional Australian population, with similar prevalence to large European 
      registries. This highlights the need for improved access to specialised services 
      in regional and rural areas to reduce adverse cardiovascular (CV) outcomes.
CI  - Copyright (c) 2020 Australian and New Zealand Society of Cardiac and Thoracic 
      Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). 
      Published by Elsevier B.V. All rights reserved.
FAU - Samuel, Rohit
AU  - Samuel R
AD  - Department of Cardiology, Barwon Heath, Geelong, Vic, Australia. Electronic 
      address: rsamuel23@gmail.com.
FAU - Birdsey, Garth
AU  - Birdsey G
AD  - Department of Cardiology, Barwon Heath, Geelong, Vic, Australia; Faculty of 
      Health, Deakin University, Melbourne, Vic, Australia.
FAU - Amerena, John
AU  - Amerena J
AD  - Department of Cardiology, Barwon Heath, Geelong, Vic, Australia; Faculty of 
      Health, Deakin University, Melbourne, Vic, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - 0 (Cholesterol, LDL)
SB  - IM
MH  - *Acute Coronary Syndrome/diagnosis/epidemiology/etiology
MH  - Australia/epidemiology
MH  - Cholesterol, LDL
MH  - Coronary Care Units
MH  - Humans
MH  - *Hyperlipoproteinemia Type II/complications/diagnosis/drug therapy
MH  - Middle Aged
MH  - Prevalence
MH  - Risk Factors
OTO - NOTNLM
OT  - Familial hypercholesterolaemia
OT  - Preventative cardiology
EDAT- 2020/11/03 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/11/02 05:38
PHST- 2019/02/24 00:00 [received]
PHST- 2020/08/26 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/11/02 05:38 [entrez]
AID - S1443-9506(20)31415-3 [pii]
AID - 10.1016/j.hlc.2020.09.929 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2021 May;30(5):730-733. doi: 10.1016/j.hlc.2020.09.929. Epub 
      2020 Oct 29.